Why the study?
Although ticagrelor and prasugrel are standard antiplatelet treatments in ACS, many patients still require clopidogrel, and the influence of ACS and genetic variability on clopidogrel active metabolite levels and platelet inhibition needed evaluation.
Does acute coronary syndrome affect the levels of clopidogrel active metabolite and platelet inhibition compared to stable coronary artery disease in patients undergoing PCI?
Does acute coronary syndrome affect the levels of clopidogrel active metabolite and platelet inhibition compared to stable coronary artery disease in patients undergoing PCI?
Acute coronary syndrome does not significantly alter the levels of clopidogrel active metabolite or platelet inhibition compared to stable coronary artery disease, regardless of CYP2C19 or ABCB1 gene polymorphisms.
Clopidogrel exposure and platelet response appear comparable in ACS versus stable CAD; leaves open whether genetic testing refines dosing in Killip I–III patients.
INTRODUCTION: Although ticagrelor and prasugrel remain the standard antiplatelet treatments in acute coronary syndrome (ACS), numerous patients still present with indications for clopidogrel use. AIM: ) of clopidogrel to exclude the effect of genetic variability on drug concentrations and activity. MATERIAL AND METHODS: This single-center, open-label, prospective study included 199 patients hospitalized due to ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) in Killip class I-III, who underwent percutaneous coronary intervention. The control group included 22 patients with stable coronary artery disease. RESULTS: polymorphism was observed in the study subgroups. CONCLUSIONS: gene polymorphisms.
No takes yet. Share an insight, caveat, or question.
Wójcik et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: